How to buy Medicenna Therapeutics stock

Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

Medicenna Therapeutics share price

Use our graph to track the performance of MDNA stocks over time.

Medicenna Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-14.

52-week range	$2.20 - $6.84
50-day moving average	$3.97
200-day moving average	$4.05
Wall St. target price	N/A
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Medicenna Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Medicenna Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Medicenna Therapeutics Corp by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medicenna Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-41.1%
Return on equity TTM	-71.85%
Profit margin	0%
Book value	N/A
Market capitalisation	$216.1 million

TTM: trailing 12 months

Shorting Medicenna Therapeutics shares

There are currently 268,568 Medicenna Therapeutics shares held short by investors – that's known as Medicenna Therapeutics's "short interest". This figure is 45.2% up from 184,976 last month.

There are a few different ways that this level of interest in shorting Medicenna Therapeutics shares can be evaluated.

Medicenna Therapeutics's "short interest ratio" (SIR)

Medicenna Therapeutics's "short interest ratio" (SIR) is the quantity of Medicenna Therapeutics shares currently shorted divided by the average quantity of Medicenna Therapeutics shares traded daily (recently around 172158.97435897). Medicenna Therapeutics's SIR currently stands at 1.56. In other words for every 100,000 Medicenna Therapeutics shares traded daily on the market, roughly 1560 shares are currently held short.

However Medicenna Therapeutics's short interest can also be evaluated against the total number of Medicenna Therapeutics shares, or, against the total number of tradable Medicenna Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medicenna Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Medicenna Therapeutics shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Medicenna Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medicenna Therapeutics.

Find out more about how you can short Medicenna Therapeutics stock.

Medicenna Therapeutics share dividends

We're not expecting Medicenna Therapeutics to pay a dividend over the next 12 months.

Medicenna Therapeutics share price volatility

Over the last 12 months, Medicenna Therapeutics's shares have ranged in value from as little as $2.195 up to $6.84. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics's is 0.6631. This would suggest that Medicenna Therapeutics's shares are less volatile than average (for this exchange).

Medicenna Therapeutics overview

Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada. .

Frequently asked questions

• What percentage of Medicenna Therapeutics is owned by insiders or institutions?

  Currently 30.708% of Medicenna Therapeutics shares are held by insiders and 5.215% by institutions.

• How many people work for Medicenna Therapeutics?

  Latest data suggests 7 work at Medicenna Therapeutics.

• When does the fiscal year end for Medicenna Therapeutics?

  Medicenna Therapeutics's fiscal year ends in March.

• Where is Medicenna Therapeutics based?

  Medicenna Therapeutics's address is: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2

• What is Medicenna Therapeutics's ISIN number?

  Medicenna Therapeutics's international securities identification number is: CA58490H1073